Oncology biosimilars: New developments and future directions-Reference-Cited by-同舟云学术

Oncology biosimilars: New developments and future directions

Published:2022-10-04 Issue:11 Volume:5 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Bachu Rinda Devi¹,Abou‐Dahech Mariam¹^ORCID,Balaji Swapnaa¹,Boddu Sai H. S.²³,Amos Samson⁴,Singh Vishal⁵,Babu R. Jayachandra⁶,Tiwari Amit K.¹³⁷^ORCID

Affiliation:

1. Department of Pharmacology and Experimental Therapeutics College of Pharmacy & Pharmaceutical Sciences, University of Toledo Toledo Ohio USA

2. College of Pharmacy and Health Sciences Ajman University Ajman UAE

3. Center of Medical and Bio‐allied Health Sciences Research Ajman University Ajman UAE

4. Department of Pharmaceutical Sciences Cedarville University School of Pharmacy Cedarville Ohio USA

5. Department of Nutrition Pennsylvania State University State College Pennsylvania USA

6. Department of Drug Discovery & Development Harrison School of Pharmacy, Auburn University Auburn Alabama USA

7. Department of Cell and Cancer Biology College of Medicine & Life Sciences, University of Toledo Toledo Ohio USA

Funder

U.S. Department of Defense

Susan G. Komen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1720

Reference196 articles.

1. U.S. Food & Drug Administration (FDA).Biosimilar and Interchangeable Products. Accessed June 19 2022Available from:https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products#generic.

2. Clinical experience with Zarzio® in Europe: what have we learned?

3. U.S. Food & Drug Administration.Guidance Document. Scientific Considerations in Demonstrating Biosimilarity to a Reference product. Accessed April 14 2021. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.

4. European Medicines Agency.Biosimilar Medicines: Overview. Accessed April 14 2021. Available from:https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview.

5. The rise of oncology biosimilars: from process to promise

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-29

2. Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer;EMJ Oncology;2023-10-02

3. Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer;EMJ Oncology;2023-10-02

4. Emerging themes and factors influencing the prices of biotherapeutics;World Medical & Health Policy;2023-05-02

5. Biosimilars: Promising and Rapidly Emerging Biotherapeutics;Novel Technologies in Biosystems, Biomedical & Drug Delivery;2023